Institutions: Bank of England Expected to Cut Interest Rates by Another 75 Basis Points This Year
Pantheon Macroeconomics Chief UK Economist Robert Wood stated that the forecast for UK economic growth in 2025 and 2026 has been revised downwards, with GDP now expected to grow by 0.9% and 1% in 2025 and 2026, respectively, lower than the previous forecasts of 1.1% and 1.5%. Although the inflation rate fell to 2.6% in March, it is expected to rise significantly in the coming months, potentially reaching 3.4% in the second quarter and only dropping to 3.3% by the end of the year. Most of the data since the last forecast assessment would typically lead the MPC to maintain an absolutely cautious stance. However, President Trump's tariffs have already disrupted the global economy and unsettled financial markets. In this context, Pantheon Macroeconomics expects the Bank of England to implement three more 25 basis point rate cuts this year, including consecutive cuts in May and June, and a final cut in November. (Jin10)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
BUZZ - Reports suggest Starbucks had discussed a deal, Chipotle shares rise
Latest Updates October 8 - Chipotle Mexican Grill shares (CMG.N) surged by as much as 8.55% to $33.40, while Starbucks (SBUX.O) shares once dropped 6.66% to $87.35. The Financial Times, citing insiders, reported that Starbucks (SBUX) had considered acquiring Chipotle (link). The coffee giant's stock has fallen to its lowest point since March. According to the report, the progress of the acquisition plan remains unclear; both Starbucks and Chipotle did not immediately respond to Reuters' requests for comment. If the deal goes through, CEO Brian Niccol would return to lead the Mexican grill chain he ran before joining the coffee giant two years ago. "For SBUX, we think investors would view this as a distraction for management's time and energy—after all, there is still much work to be done to revive the Starbucks brand, particularly concerning the fundamentals of same-store sales in North America, as the company gradually exhausts easily achievable growth points through 2027 and beyond," said RBC Capital Markets analyst Logan Reich. According to data from the London Stock Exchange Group (LSEG), CMG has a market capitalization of about $39 billions, while SBUX is valued at $107 billions. As of the close of the last trading day, SBUX has risen about 11% year-to-date, while CMG has fallen by 17%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may be inaccurate or lack contextual nuances, Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters accepts no liability for any loss or damage arising from the use of automated translations.)
Investment Bank TD Cowen Revises Price Targets for Bitcoin (BTC)! Bear or Bull? Here are the Details
Market Chatter: Nvidia-Backed Firmus Grid Seen Delaying IPO
02:12 PM EDT, 10/08/2026 (MT Newswires) -- Nvidia-backed (NVDA) Firmus Grid is poised to delay its initial public offering amid slack investor demand, Bloomberg News reported Thursday, citing people familiar with the matter. The Australian data center company had been looking to raise as much as $5.5 billion including an overallotment option, indicating a $30.4 billion valuation, and may consider a private funding round instead, the report said. Firmus didn't immediately reply to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 230.30, Change: -7.17, Percent Change: -3.02
Crypto prices
More
